Casirivimab (REGN10933), a human monoclonal antibody targeting the SARS-CoV-2 virus responsible for COVID-19, demonstrates reduced efficacy against emerging variants. When combined with Imdevimab, it significantly lowers viral load and enhances disease outcomes [1].
CAS Nummer:
[2415933-42-3]
Target-Kategorie:
SARS-CoV
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten